Theranostics · 2020 · 31 citations · 0 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCancer MetabolismHepatocellular CarcinomaMetabolic Reprogramming In CancerOncogenic Signaling PathwaysRetinoic Acid SignalingGlycogen Synthase Kinase 3 SignalingLuciferase Reporter AssaysLuciferase ReportersRetinoblastoma-related Protein PathwayRetinoid MetabolismRetinoid Receptor SignalingRetinoid X ReceptorsSorafenib Therapy
: Our findings demonstrate that GSK-3β is a disruptor of retinoid signalling and a new resistant factor of sorafenib in HCC. Targeting GSK-3β may be a promising strategy for HCC treatment in clinic.